CytoSorbents - Public Comps and Valuation Multiples

CytoSorbents Overview

About CytoSorbents

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Founded

2014

HQ

Employees

149

Website

cytosorbents.com

Sectors

Medical Devices
HealthTech
DeepTech

Financials

LTM Revenue $38.7M

Last FY EBITDA -$19.3M

EV

$69.8M

Valuation Multiples

Multiples.vc

Valuation Multiples for 12K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

CytoSorbents Financials

CytoSorbents has a last 12-month revenue (LTM) of $38.7M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, CytoSorbents achieved revenue of $35.6M and an EBITDA of -$19.3M.

CytoSorbents expects next 12-month revenue of XXX and NTM EBITDA of XXX

See CytoSorbents valuation multiples based on analyst estimates

CytoSorbents P&L

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$38.7M	XXX	$35.6M	XXX	XXX	XXX
Gross Profit	$27.4M	XXX	$25.1M	XXX	XXX	XXX
Gross Margin	71%	XXX	71%	XXX	XXX	XXX
EBITDA	n/a	XXX	-$19.3M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	-54%	XXX	XXX	XXX
EBIT	-$13.8M	XXX	-$16.8M	XXX	XXX	XXX
EBIT Margin	-36%	XXX	-47%	XXX	XXX	XXX
Net Profit	-$15.6M	XXX	-$20.7M	XXX	XXX	XXX
Net Margin	-40%	XXX	-58%	XXX	XXX	XXX
Net Debt	XXX	XXX	$10.7M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

CytoSorbents Stock Performance

As of May 30, 2025, CytoSorbents's stock price is $1.

CytoSorbents has current market cap of $54.4M, and EV of $69.8M.

See CytoSorbents trading valuation data

CytoSorbents Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$69.8M	$54.4M	XXX	XXX	XXX	XXX	$-0.19

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

CytoSorbents Valuation Multiples

As of May 30, 2025, CytoSorbents has market cap of $54.4M and EV of $69.8M.

CytoSorbents's trades at 2.0x EV/Revenue multiple, and -3.6x EV/EBITDA.

Equity research analysts estimate CytoSorbents's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

CytoSorbents has a P/E ratio of -3.5x.

See valuation multiples for CytoSorbents and 12K+ public comps

CytoSorbents Financial Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$54.4M	XXX	$54.4M	XXX	XXX	XXX
EV (current)	$69.8M	XXX	$69.8M	XXX	XXX	XXX
EV/Revenue	1.8x	XXX	2.0x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-3.6x	XXX	XXX	XXX
EV/EBIT	-5.1x	XXX	-4.2x	XXX	XXX	XXX
EV/Gross Profit	2.5x	XXX	n/a	XXX	XXX	XXX
P/E	-3.5x	XXX	-2.6x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-4.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get CytoSorbents Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

CytoSorbents Margins & Growth Rates

CytoSorbents's last 12 month revenue growth is 22%

CytoSorbents's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.

CytoSorbents's rule of 40 is -72% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

CytoSorbents's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for CytoSorbents and other 12K+ public comps

CytoSorbents Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	22%	XXX	22%	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	-54%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	-72%	XXX	-32%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	19%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	118%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial